<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254565</url>
  </required_header>
  <id_info>
    <org_study_id>KAI-4169-003</org_study_id>
    <secondary_id>20120330</secondary_id>
    <nct_id>NCT01254565</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KAI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KAI Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and tolerability and efficacy of
      multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of
      secondary hyperparathyroidism (HPT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 20, 2011</start_date>
  <completion_date type="Actual">August 24, 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Mean Pre-hemodialysis Parathyroid Hormone (PTH) During the Efficacy Assessment Phase</measure>
    <time_frame>Baseline and the efficacy assessment phase (EAP; defined as the period between 3 days before and 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
    <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase</measure>
    <time_frame>Baseline and the efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
    <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Parathyroid Hormone ≤ 300 pg/mL During the Efficacy Assessment Phase</measure>
    <time_frame>Efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
    <description>The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Corrected Calcium (cCa) During the Efficacy Assessment Phase</measure>
    <time_frame>Baseline and the efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
    <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Phosphorus (P) During the Efficacy Assessment Phase</measure>
    <time_frame>Baseline and the efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
    <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Corrected Calcium Phosphorus Product (cCa x P) During the Efficacy Assessment Phase</measure>
    <time_frame>Baseline and the efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
    <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Phosphorus ≤ 4.5 mg/dL or ≤ 5.5 mg/dL During the Efficacy Assessment Phase</measure>
    <time_frame>Efficacy assessment phase</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Etelcalcetide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etelcalcetide</intervention_name>
    <description>Administered intravenously (IV) at the end of hemodialysis</description>
    <arm_group_label>Etelcalcetide</arm_group_label>
    <other_name>KAI-4169</other_name>
    <other_name>AMG 416</other_name>
    <other_name>Parsabiv™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered intravenously at the end of hemodialysis</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject provides written informed consent.

          -  Intact parathyroid hormone (PTH) at least 350 pg/mL.

          -  Corrected calcium at least 9.0 mg/dL.

          -  Hemoglobin at least 9.0 g/dL.

          -  Adequate hemodialysis three times per week.

          -  Excepting chronic renal failure, subject is judged to be in stable medical condition
             based on medical history, physical examination, and routine laboratory tests.

        Exclusion Criteria:

          -  History or symptomatic ventricular dysrhythmias.

          -  History of angina pectoris or congestive heart failure

          -  History of myocardial infarction, coronary angioplasty, or coronary artery bypass
             grafting within the past 6 months.

          -  History of or treatment for seizure disorder.

          -  Recent (3 months) parathyroidectomy.

          -  Serum transaminases (alanine aminotransferase, aspartate aminotransferase) greater
             than two times the upper limit of normal at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M D</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <results_first_submitted>March 1, 2017</results_first_submitted>
  <results_first_submitted_qc>March 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2017</results_first_posted>
  <disposition_first_submitted>July 8, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 8, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 30, 2015</disposition_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical Trial, Phase 2</keyword>
  <keyword>Renal Dialysis</keyword>
  <keyword>Secondary Hyperparathyroidism</keyword>
  <keyword>Parathyroid hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 11 study centers in the United States from 17 February 2011 (first participant enrolled) to 24 August 2011 (last participant completed follow up). A total of 87 patients with secondary hyperparathyroidism (HPT) receiving hemodialysis were enrolled and randomized in the study.</recruitment_details>
      <pre_assignment_details>This was a multiple-ascending dose study consisting of 3 cohorts: Cohort 1 participants were randomized in a 3:2 ratio to receive etelcalcetide or placebo for 2 weeks; Cohorts 2 and 3 were randomized in a 1:1 ratio to receive etelcalcetide or placebo for 4 weeks. Randomization was stratified by serum parathyroid hormone (&lt; 600 or ≥ 600 pg/mL).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Etelcalcetide 5 mg</title>
          <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2: Etelcalcetide 10 mg</title>
          <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 3: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 3: Etelcalcetide 5 mg</title>
          <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-compliance to Study Procedures</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one 1 dose of investigational product (the modified intent-to-treat [mITT] population)</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: Etelcalcetide 5 mg</title>
          <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2: Etelcalcetide 10 mg</title>
          <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 3: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 3: Etelcalcetide 5 mg</title>
          <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="13"/>
            <count group_id="B7" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="16.66"/>
                    <measurement group_id="B2" value="54.0" spread="10.00"/>
                    <measurement group_id="B3" value="52.4" spread="13.65"/>
                    <measurement group_id="B4" value="50.7" spread="13.60"/>
                    <measurement group_id="B5" value="56.7" spread="11.61"/>
                    <measurement group_id="B6" value="59.6" spread="10.99"/>
                    <measurement group_id="B7" value="53.7" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Screening Serum Parathyroid Hormone (PTH)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 600 pg/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 600 pg/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parathyroid Hormone</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="636.3" spread="191.64"/>
                    <measurement group_id="B2" value="588.3" spread="250.52"/>
                    <measurement group_id="B3" value="601.5" spread="239.20"/>
                    <measurement group_id="B4" value="765.1" spread="480.82"/>
                    <measurement group_id="B5" value="619.4" spread="310.35"/>
                    <measurement group_id="B6" value="662.1" spread="442.01"/>
                    <measurement group_id="B7" value="659.4" spread="361.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corrected Calcium</title>
          <population>Corrected calcium data were missing for 2 participants in Cohort 3.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.1" spread="0.84"/>
                    <measurement group_id="B2" value="9.3" spread="0.44"/>
                    <measurement group_id="B3" value="9.8" spread="0.62"/>
                    <measurement group_id="B4" value="9.7" spread="0.59"/>
                    <measurement group_id="B5" value="9.3" spread="0.58"/>
                    <measurement group_id="B6" value="9.7" spread="0.62"/>
                    <measurement group_id="B7" value="9.6" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Phosphorus</title>
          <population>Phosphorus values were not collected at Baseline for Cohort 1; data were missing for 7 participants in Cohort 2 and 2 participants in Cohort 3.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="18"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="6.5" spread="1.83"/>
                    <measurement group_id="B4" value="5.7" spread="1.18"/>
                    <measurement group_id="B5" value="5.2" spread="1.17"/>
                    <measurement group_id="B6" value="5.0" spread="1.02"/>
                    <measurement group_id="B7" value="5.7" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Mean Pre-hemodialysis Parathyroid Hormone (PTH) During the Efficacy Assessment Phase</title>
        <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
        <time_frame>Baseline and the efficacy assessment phase (EAP; defined as the period between 3 days before and 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Etelcalcetide 10 mg</title>
            <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Pre-hemodialysis Parathyroid Hormone (PTH) During the Efficacy Assessment Phase</title>
          <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
          <population>Modified intent-to-treat population</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="17.11"/>
                    <measurement group_id="O2" value="-19.4" spread="20.65"/>
                    <measurement group_id="O3" value="28.5" spread="70.39"/>
                    <measurement group_id="O4" value="-49.4" spread="20.42"/>
                    <measurement group_id="O5" value="2.3" spread="29.44"/>
                    <measurement group_id="O6" value="-33.0" spread="26.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The hypothesis for this study (Cohorts 2 and 3) was that intravenous administration of etelcalcetide is superior to placebo for the reduction of PTH after TIW dosing in hemodialysis patients with secondary HPT. This hypothesis was tested in Cohorts 2 and 3 by comparing the mean percent changes from baseline in pre-hemodialysis PTH levels collected during the efficacy phase between the etelcalcetide and placebo groups within each cohort.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The primary endpoint was tested at the 0.05 level (1-sided).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>A rank analysis of variance (ANOVA) model with treatment and screening PTH (&lt; 600 pg/mL or ≥ 600 pg/mL) as factors.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-76.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.9</ci_lower_limit>
            <ci_upper_limit>-50.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The hypothesis for this study (Cohorts 2 and 3) was that intravenous administration of etelcalcetide is superior to placebo for the reduction of PTH after TIW dosing in hemodialysis patients with secondary HPT. This hypothesis was tested in Cohorts 2 and 3 by comparing the mean percent changes from baseline in pre-hemodialysis PTH levels collected during the efficacy phase between the etelcalcetide and placebo groups within each cohort.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The primary endpoint was tested at the 0.05 level (1-sided).</non_inferiority_desc>
            <p_value>0.0032</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with treatment and screening PTH (&lt; 600 pg/mL or ≥ 600 pg/mL) as factors.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-36.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.8</ci_lower_limit>
            <ci_upper_limit>-13.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase</title>
        <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
        <time_frame>Baseline and the efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Etelcalcetide 10 mg</title>
            <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase</title>
          <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="9.5"/>
                    <measurement group_id="O4" value="76.2"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0968</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Parathyroid Hormone ≤ 300 pg/mL During the Efficacy Assessment Phase</title>
        <description>The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
        <time_frame>Efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Etelcalcetide 10 mg</title>
            <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Parathyroid Hormone ≤ 300 pg/mL During the Efficacy Assessment Phase</title>
          <description>The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="7.7"/>
                    <measurement group_id="O6" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0730</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Corrected Calcium (cCa) During the Efficacy Assessment Phase</title>
        <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
        <time_frame>Baseline and the efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
        <population>Modified intent-to-treat population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Etelcalcetide 10 mg</title>
            <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Corrected Calcium (cCa) During the Efficacy Assessment Phase</title>
          <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
          <population>Modified intent-to-treat population with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.76"/>
                    <measurement group_id="O2" value="-7.3" spread="2.62"/>
                    <measurement group_id="O3" value="-1.7" spread="6.25"/>
                    <measurement group_id="O4" value="-13.0" spread="10.17"/>
                    <measurement group_id="O5" value="1.0" spread="5.26"/>
                    <measurement group_id="O6" value="-6.0" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>A rank ANOVA model with treatment and screening PTH (&lt; 600 or ≥ 600 pg/mL) as factors.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.4</ci_lower_limit>
            <ci_upper_limit>-8.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0235</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model with treatment and screening PTH (&lt; 600 or ≥ 600 pg/mL) as factors.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.8</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Phosphorus (P) During the Efficacy Assessment Phase</title>
        <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
        <time_frame>Baseline and the efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
        <population>Modified intent-to-treat population with available data; Phosphorus data were not collected at baseline for participants in Cohort 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Etelcalcetide 10 mg</title>
            <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Phosphorus (P) During the Efficacy Assessment Phase</title>
          <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
          <population>Modified intent-to-treat population with available data; Phosphorus data were not collected at baseline for participants in Cohort 1.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.4" spread="17.92"/>
                    <measurement group_id="O4" value="-2.4" spread="26.86"/>
                    <measurement group_id="O5" value="14.1" spread="36.05"/>
                    <measurement group_id="O6" value="-7.3" spread="12.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2255</p_value>
            <method>ANOVA</method>
            <method_desc>A rank ANOVA model with treatment and screening PTH (&lt; 600 or ≥ 600 pg/mL) as factors.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.6</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1751</p_value>
            <method>ANOVA</method>
            <method_desc>A rank ANOVA model with treatment and screening PTH (&lt; 600 or ≥ 600 pg/mL) as factors.</method_desc>
            <param_type>LS mean Difference</param_type>
            <param_value>-21.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.8</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Corrected Calcium Phosphorus Product (cCa x P) During the Efficacy Assessment Phase</title>
        <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
        <time_frame>Baseline and the efficacy assessment phase (from 3 days before to 3 days after the last dose of study drug; approximately 2 weeks for Cohort 1 and 4 weeks for Cohorts 2 and 3)</time_frame>
        <population>Modified intent-to-treat population with available data; Phosphorus data were not collected at baseline for participants in Cohort 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Etelcalcetide 10 mg</title>
            <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Corrected Calcium Phosphorus Product (cCa x P) During the Efficacy Assessment Phase</title>
          <description>Baseline is defined as the average of pre-hemodialysis values obtained on day -2 and day 1. The efficacy assessment phase (defined as 3 days before and 3 days after the last dose of investigational product) value is the mean of all predialysis values obtained during that period.</description>
          <population>Modified intent-to-treat population with available data; Phosphorus data were not collected at baseline for participants in Cohort 1.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-0.3" spread="16.25"/>
                    <measurement group_id="O4" value="-11.0" spread="32.32"/>
                    <measurement group_id="O5" value="14.7" spread="35.79"/>
                    <measurement group_id="O6" value="-12.6" spread="14.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0112</p_value>
            <method>ANOVA</method>
            <method_desc>A rank ANOVA model with treatment and screening PTH (&lt; 600 or ≥ 600 pg/mL) as factors.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.8</ci_lower_limit>
            <ci_upper_limit>-4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0554</p_value>
            <method>ANOVA</method>
            <method_desc>A rank ANOVA model with treatment and screening PTH (&lt; 600 or ≥ 600 pg/mL) as factors.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-27.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.3</ci_lower_limit>
            <ci_upper_limit>-1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Phosphorus ≤ 4.5 mg/dL or ≤ 5.5 mg/dL During the Efficacy Assessment Phase</title>
        <time_frame>Efficacy assessment phase</time_frame>
        <population>Modified intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW) for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Etelcalcetide 10 mg</title>
            <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Placebo</title>
            <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: Etelcalcetide 5 mg</title>
            <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Phosphorus ≤ 4.5 mg/dL or ≤ 5.5 mg/dL During the Efficacy Assessment Phase</title>
          <population>Modified intent to treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phosphorus ≤ 4.5 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="47.6"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus ≤ 5.5 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="53.8"/>
                    <measurement group_id="O6" value="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug through to day 41 (Cohort 1) or day 55 (Cohorts 2 and 3).</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: Etelcalcetide 5 mg</title>
          <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 2 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2: Etelcalcetide 10 mg</title>
          <description>Participants received 10 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3: Placebo</title>
          <description>Participants received placebo administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 3: Etelcalcetide 5 mg</title>
          <description>Participants received 5 mg etelcalcetide administered by intravenous injection at the end of each hemodialysis session TIW for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen, Inc</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

